HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

VCYT

Veracyte, Inc. (Russell 2000)

Healthcare — Diagnostics & Research

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Buy 1.6 / 5 12 analysts
$44.19
$-1.85 (-4.02%)
Target: $58.42 (32.2%)

Price History

52-Week Range
Sign in to add VCYT to a watchlist or set price alerts.

Fundamentals

Market Cap$3.55B
P/E Ratio (TTM)31.56
Forward P/E22.65
EPS (TTM)$1.40
Dividend Yield-
Profit Margin20.37%
Revenue Growth15.50%
ROE8.77%
Debt/Equity2.89
Recommendation Buy 1.6
Analyst Target$58.42
Analysts12
Next Earnings Jul 30, 2026 AMC
Indexes Russell 2000

Technical Indicators

RSI (14)58.0
Beta1.93
SMA 20$43.04
SMA 40$43.36
52-Week High$60.91
52-Week Low$29.46
50-Day Avg$45.46
200-Day Avg$42.49
Avg Volume$1.34M
Volume$1.43M

Performance Analysis

BULLISH

VCYT shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 47% of its 52-week range.
+ RSI at 58.0 shows positive momentum.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
~ Modest revenue growth of 15.5% year-over-year.
+ Healthy profit margin of 20.4%.
+ Wall Street consensus is "Buy" from 12 analysts.
+ Average analyst target of $58.42 implies 32.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report